Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).1 In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.2 Resolvin D5 (RvD5) is a DHA-derived resolvin generated by a double dioxygenation mechanism.3 RvD5 has been identified in media from ionophore-stimulated trout brain cells, in human synovial fluid from patients with rheumatoid arthritis, and in exudates of bacterial infections in mice.4,5,6 RvD5 stimulates the phagocytosis of E. coli by human macrophages, and RvD5 methyl ester enhances bacterial killing in mice inoculated with E. coli.6
WARNING This product is not for human or veterinary use.
1. Novel docosatrienes and 17S-
2. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol. 28(4), 176-183 (2007).
3. Anti-
4. Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-
5. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-
6. Infection regulates pro-
Human and mouse eosinophils differ in their ability to biosynthesize eicosanoids, docosanoids, the endocannabinoid 2-
High levels of eicosanoids and docosanoids in the lungs of intubated COVID-
Pulmonary infection induces persistent, pathogen-
Quantitative profiling of inflammatory and pro-
Lipid storm within the lungs of severe COVID-
Development of an optimized LC-
Apolipoprotein A-
Lipid Mediator Metabolomics via LC-